References
- Bezwoda W R. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAP) chemotherapy for high risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol 1999; 18: 4, abstract
- Scandinavian Breast Cancer Study Group 9401. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus doses escalated and tailed FEC therapy. Proc Am Soc Clin Oncol 1999; 18: 3, abstract
- Peters W, Rosner G, Vredenburgh J. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114, NCIC MA-13. Proc Am Soc Clin Oncol 1999; 18: 2, abstract
- Stadtmauer E A, O'Neill A, Goldstein L J. Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The “Philadelphia” Intergroup study (PBT-1). Proc Am Soc Clin Oncol 1999; 18: 1, abstract
- Jones SE., Moon T E, Bonadonna G. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history database. Am J Clin Oncol 1987; 10: 387–395
- Somlo G, Doroshow J H, Forrnan S J. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 1997; 15: 2882–2893
- Nieto Y, Cagnoni P J, Xu X. Predictive model for relapse after high-dose chemotherapy (HDCT) with peripheral blood progenitor cell (PBPC) support for high-risk primary breast cancer. Proc Am Soc Clin Oncol 1998; 17: 456, abstract
- Greenberg P A, Hortobagyi G N, Smith T L. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–2205
- Swenerton K D, Legha S S, Smith T. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39: 1552–1562
- Antman K, Ayash L, Elias A. A phase II study of high-dose cyclophosphamide, thiotepa. and carboplatin with autologous bone marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–110
- Peters W P, Shpall E J, Jones R B. High-dose combination cyclophosphamide (CPA), cisplatin (cDDP) and carmustine with bone marrow support as initial treatment for metastatic breast cancer: 3- to 6-year follow-up. Proc Am Soc Clin Oncol 1990; 9: 31, abstract
- Williams S F, Gilewski T, Mick R. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743–1747
- Friedman L M, Furberg C D, DeMets D L. Fundamentals of Clinical Trials, 3rd ed. Mosby, New York 1995; 204
- Dunphy F R, Spitzer G, Rossiter Fornoff J E. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994; 73: 2157–2167
- Ayash L J, Wheeler C, Faircloth D. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043–2049
- Nieto Y, Cagnoni P J, Shpall E J. Phase II trial of high-dose chemotherapy with autologous stem cell transplantation for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res 1999; 5: 1731–1737